BENTONVILLE, AR, March 1, 2021 — OTC PR WIRE –– GLUCODOWN® (OTC Pink: GLUC) revenues at Amazon for the month of February 2021 were $52,419 – a 362% increase compared to February 2020 revenues of $11,349. Sequentially, February 2021 revenues of $52,419 at Amazon, exceeded January 2021 revenues of $34,551, a 51% increase. Importantly, during February 2021 most GLUCODOWN® listings at Amazon were in-stock and available for purchase.
For further comparison, Glucose Health, Inc.’s total Q1 fiscal 2020 revenues (from all retailer partners including Walmart) were $82,613. For just the first two months of Q1 fiscal 2021, Amazon revenues alone, were $86,890.
Glucose Health, Inc. (OTC Pink: GLUC) will release its fiscal 2020 annual report and first quarter 2021 revenue update, Wednesday March 31, 2021.
CEO Murray Fleming stated: “GLUCODOWN® is an entirely original product – no other beverage company, multinational or start-up, past or present, has ever conceived of taking a ubiquitous soft drink, iced tea, and painstakingly re-formulating it into the perfect beverage choice for upwards of 100 million persons – America’s growing population of diabetics and pre-diabetics. While GLUCODOWN®’s revenue growth trajectory is impressive, the fact is our brand is only in the very earliest stages of being discovered by this massive consumer segment.”
About Glucose Health, Inc. (OTC Pink: GLUC)
More than 100 million Americans are estimated to be diabetic or pre-diabetic, by the Centers for Disease Control and Prevention.2 Introduced in 2018 and manufactured by Glucose Health, Inc., the GLUCODOWN® brand has come to define an entirely new and distinct dietary supplement category – functional, diabetic friendly, beverages. By specializing in producing delicious and efficacious beverages nutritionally appropriate1 for the nation’s 100+ million pre and Type-2 diabetics, GLUCODOWN® is uniquely and strongly positioned among all up & coming beverage companies in America. Glucose Health, Inc. is a publicly traded company with the ticker symbol (OTC: GLUC).
For more GLUC news visit www.glucosehealthinc.com
Like us on Facebook at www.facebook.com/glucodown
1 For citations visit www.glucodown.com/clinical-data
2 National Diabetes Statistics Review, 2020; Centers for Disease Control and Prevention, Department of Health and Human Services.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and while Glucose Health, Inc. is not subject to the 1934 Securities and Exchange Act, contains forward-looking statements within the meaning Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential, “possible,” “probable, “believes,” “seeks,” “may, “will, “should,” “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Glucose Health, Inc.